𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Transcriptomic analysis of intestinal fibrosis-associated gene expression in response to medical therapy in Crohn's disease

✍ Scribed by John P. Burke; Marc Ferrante; Karen Dejaegher; R. William G. Watson; Neil G. Docherty; Gert De Hertogh; Severine Vermeire; Paul Rutgeerts; Andre D'Hoore; Freddy Penninckx; Karel Geboes; Gert Van Assche; P. Ronan O'Connell


Publisher
John Wiley and Sons
Year
2008
Tongue
English
Weight
184 KB
Volume
14
Category
Article
ISSN
1078-0998

No coin nor oath required. For personal study only.

✦ Synopsis


Background: Glucocorticoids and monoclonal antibodies to tumor necrosis factor reduce inflammation in Crohn's disease (CD). Rapid luminal healing, however, may promote intestinal stricture formation. The aim of this study was to examine fibrosis-associated gene expression in the intestine of patients with CD and correlate expression levels with prior medical therapies.

Methods:

In all, 37 patients with stricturing CD and 18 non-CD controls underwent a transmural biopsy at the time of elective intestinal resection. Quantitative real-time polymerase chain reaction (PCR) was conducted to determine differential mRNA expression of TGF-␤ 1 , Smad-7, CTGF, collagen-1␣, fibronectin, BMP-7, and MIF. Intestinal fibroblasts were treated in vitro with dexamethasone.

Results: Relative to control, strictured CD intestinal tissue expressed increased TGF-␤ 1 , CTGF, collagen-1␣, and BMP-7 (all P Ͻ 0.05). TGF-␤ 1 gene expression positively correlated with the expression of its downstream targets (all P Ͻ 0.001). Preoperative infliximab exposure was not associated with increased expression in any of the target genes nor did the number of infliximab infusions correlate with gene expression. The number of cycles of corticosteroid treatment preoperatively was positively associated with CTGF (r ϭ 0.486, P ϭ 0.016) and MIF (r ϭ 0.524, P ϭ 0.009) expression. Intestinal fibroblasts treated in vitro with dexamethasone upregulated CTGF expression (P ϭ 0.023).

Conclusions: Exposure to infliximab does not appear to induce a profibrotic transcriptional response in the CD intestine. Previous corticosteroid treatment is associated with increased expression of CTGF and MIF. Treating intestinal fibroblasts in vitro with steroids upregulates CTGF expression.


📜 SIMILAR VOLUMES


Characterization of intestinal gene expr
✍ Colin L. Noble; Alexander R. Abbas; Charles W. Lees; Jennine Cornelius; Karen To 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 484 KB

Background: Genome-wide microarray expression analysis creates a comprehensive picture of gene expression at the cellular level. The aim of this study was to investigate differential intestinal gene expression in patients with Crohn's disease (CD) and controls with subanalysis of confirmed CD suscep

Predictive value of epithelial gene expr
✍ Ingrid Arijs; Roel Quintens; Leentje Van Lommel; Kristel Van Steen; Gert De Hert 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 432 KB

Background: Infliximab (IFX) has become the mainstay of therapy of refractory Crohn's disease (CD). However, a subset of patients shows incomplete or no response to this agent. In this study we investigated whether we could identify a mucosal gene panel to predict (non)response to IFX in CD. Method